Seattle Genetics’ President, Clay B. Siegall Takes the Company to New Heights

Clay B. Siegall is the President and CEO of Seattle Genetics. Seattle Genetics was founded in 1998. Dr. Siegall built Seattle Genetics to advance drug development, rigorous research, and scientific innovation along with the passion and dedication to serving the needy. At campus, Dr. Siegall studied cancer therapies related courses and earned a doctorate in […]

The Future of Antibody Based Therapy with Clay Siegall

Dr. Clay Siegall is the company’s (CEO) President, and Chairman. The highly accomplished doctor/scientist has a strong passion for his craft and helping others. With a Ph.D in Genetics from George Washington University and a (BS) in Zoology from the University of Maryland, Clay Siegall has the knowledge, know-how, ambition, and capabilities to take this […]

Seattle Genetics Continues To Grow Under The Guidance of Co-Founder Dr. Siegall

Seattle Genetics, Bothell-based biotech company recently announced a big increase (over 70 million) in public stock offerings. Dr. Siegall, co-founder says that after receiving a large amount of interest from Seattle Genetics investors, the company is now in the middle of the biggest financing round of its history. Proceeds from the offering will be well […]

Why Seattle Genetics is a Leading Biotechnology Company in ADC Technology

Seattle Genetics serves as a leading biotechnology company, especially on matters pertaining the development of Antibody Drug Conjugates. It was incorporated on July 15, 1997, and currently operates as a publicly traded company (NASDAQ: SGEN). Additionally, its headquarters are situated in one of the suburb areas of Seattle known as Bothell, Washington. Since its inception, […]